KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) Research & Development (2019 - 2025)

GoodRx Holdings' Research & Development history spans 7 years, with the latest figure at $28.9 million for Q4 2025.

  • For Q4 2025, Research & Development fell 8.82% year-over-year to $28.9 million; the TTM value through Dec 2025 reached $121.0 million, down 2.2%, while the annual FY2025 figure was $121.0 million, 2.2% down from the prior year.
  • Research & Development for Q4 2025 was $28.9 million at GoodRx Holdings, down from $31.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $39.6 million in Q3 2023 and bottomed at $26.2 million in Q1 2021.
  • The 5-year median for Research & Development is $31.5 million (2023), against an average of $32.5 million.
  • The largest annual shift saw Research & Development soared 153.37% in 2021 before it decreased 23.91% in 2024.
  • A 5-year view of Research & Development shows it stood at $35.1 million in 2021, then grew by 4.88% to $36.8 million in 2022, then decreased by 12.89% to $32.0 million in 2023, then dropped by 0.91% to $31.7 million in 2024, then decreased by 8.82% to $28.9 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Research & Development are $28.9 million (Q4 2025), $31.0 million (Q3 2025), and $29.9 million (Q2 2025).